Literature DB >> 18445685

PAI1 stimulates assembly of the fibronectin matrix in osteosarcoma cells through crosstalk between the alphavbeta5 and alpha5beta1 integrins.

Daniel Vial1, Paula J McKeown-Longo.   

Abstract

The plasminogen activation system regulates matrix remodeling through both proteolytic and non-proteolytic mechanisms. Studies were undertaken to determine the effects of the plasminogen activator inhibitor 1 (PAI1) on the assembly of the fibronectin matrix. The addition of PAI1 to MG-63 cells caused a 1.5- to threefold increase in the rate of fibronectin matrix assembly which was associated with an increase in beta integrin activation. PAI1 treatment led to a marked decrease in focal contacts and stress fibers, whereas tensin-containing matrix contacts remained unaffected. The effects of PAI1 on matrix assembly were independent of both urokinase-type plasminogen activator (uPA) and urokinase-type plasminogen activator receptor (uPAR), indicating that the stimulation of matrix assembly by PAI1 does not depend on its anti-proteolytic activity or on the association of uPAR with integrin receptors. Antagonists of the alphavbeta5 integrin mimicked the effect of PAI1 on cell morphology and fibronectin matrix deposition, indicating that stimulation of matrix assembly by PAI1 required disruption of the interaction between the alphavbeta5 integrin and vitronectin. Consistent with this conclusion, the Q123K PAI1 mutant which does not bind vitronectin had no effect on matrix assembly. Our data identify PAI1 as a novel regulator of fibronectin matrix assembly, and indicate that this regulation occurs through a previously undescribed crosstalk between the alphavbeta5 and alpha5beta1 integrins.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18445685      PMCID: PMC2535923          DOI: 10.1242/jcs.020149

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  34 in total

1.  The receptor for urokinase-type plasminogen activator regulates fibronectin matrix assembly in human skin fibroblasts.

Authors:  Elizabeth Monaghan; Volodia Gueorguiev; Cynthia Wilkins-Port; Paula J McKeown-Longo
Journal:  J Biol Chem       Date:  2003-11-05       Impact factor: 5.157

2.  Quantification of fibronectin matrix assembly sites using a novel ELISA assay.

Authors:  Mingzhe Zheng; Anthony Ambesi; Lin Yu; Paula J McKeown-Longo
Journal:  Matrix Biol       Date:  2006-12-29       Impact factor: 11.583

3.  Domain 2 of the urokinase receptor contains an integrin-interacting epitope with intrinsic signaling activity: generation of a new integrin inhibitor.

Authors:  Bernard Degryse; Massimo Resnati; Ralf-Peter Czekay; David J Loskutoff; Francesco Blasi
Journal:  J Biol Chem       Date:  2005-04-29       Impact factor: 5.157

4.  The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.

Authors:  J A Foekens; H A Peters; M P Look; H Portengen; M Schmitt; M D Kramer; N Brünner; F Jänicke; M E Meijer-van Gelder; S C Henzen-Logmans; W L van Putten; J G Klijn
Journal:  Cancer Res       Date:  2000-02-01       Impact factor: 12.701

5.  Regulation of fibronectin matrix assembly by activated Ras in transformed cells.

Authors:  K A Brenner; S A Corbett; J E Schwarzbauer
Journal:  Oncogene       Date:  2000-06-29       Impact factor: 9.867

6.  Inhibition of fibronectin matrix assembly by the heparin-binding domain of vitronectin.

Authors:  D C Hocking; J Sottile; T Reho; R Fässler; P J McKeown-Longo
Journal:  J Biol Chem       Date:  1999-09-17       Impact factor: 5.157

7.  Development and characterization of a conditionally immortalized human fetal osteoblastic cell line.

Authors:  S A Harris; R J Enger; B L Riggs; T C Spelsberg
Journal:  J Bone Miner Res       Date:  1995-02       Impact factor: 6.741

8.  Urokinase-type plasminogen activator receptor regulates a novel pathway of fibronectin matrix assembly requiring Src-dependent transactivation of epidermal growth factor receptor.

Authors:  Elizabeth Monaghan-Benson; Paula J McKeown-Longo
Journal:  J Biol Chem       Date:  2006-02-03       Impact factor: 5.157

Review 9.  Tumor-associated urokinase-type plasminogen activator: biological and clinical significance.

Authors:  M Schmitt; F Jänicke; N Moniwa; N Chucholowski; L Pache; H Graeff
Journal:  Biol Chem Hoppe Seyler       Date:  1992-07

10.  Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?

Authors:  G Deng; S A Curriden; S Wang; S Rosenberg; D J Loskutoff
Journal:  J Cell Biol       Date:  1996-09       Impact factor: 10.539

View more
  19 in total

1.  Plasminogen Activator Inhibitor 1 (PAI1) Promotes Actin Cytoskeleton Reorganization and Glycolytic Metabolism in Triple-Negative Breast Cancer.

Authors:  Brock A Humphries; Johanna M Buschhaus; Yu-Chih Chen; Henry R Haley; Tonela Qyli; Benjamin Chiang; Nathan Shen; Shrila Rajendran; Alyssa Cutter; Yu-Heng Cheng; Yu-Ting Chen; Jason Cong; Phillip C Spinosa; Euisik Yoon; Kathryn E Luker; Gary D Luker
Journal:  Mol Cancer Res       Date:  2019-02-04       Impact factor: 5.852

2.  The vitronectin-binding function of PAI-1 exacerbates lung fibrosis in mice.

Authors:  Anthony J Courey; Jeffrey C Horowitz; Kevin K Kim; Timothy J Koh; Margaret L Novak; Natalya Subbotina; Mark Warnock; Bing Xue; Andrew K Cunningham; Yujing Lin; Monica P Goldklang; Richard H Simon; Daniel A Lawrence; Thomas H Sisson
Journal:  Blood       Date:  2011-07-06       Impact factor: 22.113

3.  Opposing effects of collagen I and vitronectin on fibronectin fibril structure and function.

Authors:  Candace D Gildner; Daniel C Roy; Christopher S Farrar; Denise C Hocking
Journal:  Matrix Biol       Date:  2014-02-06       Impact factor: 11.583

4.  Soluble urokinase-type plasminogen activator receptor in FSGS: stirred but not shaken.

Authors:  Jochen Reiser; Harold Chapman
Journal:  J Am Soc Nephrol       Date:  2014-05-01       Impact factor: 10.121

5.  A plasminogen activator inhibitor type 1 mutant retards diabetic nephropathy in db/db mice by protecting podocytes.

Authors:  Jiandong Zhang; Chunyan Gu; Daniel A Lawrence; Alfred K Cheung; Yufeng Huang
Journal:  Exp Physiol       Date:  2014-01-17       Impact factor: 2.969

Review 6.  Cancer-associated fibroblasts drive the progression of metastasis through both paracrine and mechanical pressure on cancer tissue.

Authors:  George S Karagiannis; Theofilos Poutahidis; Susan E Erdman; Richard Kirsch; Robert H Riddell; Eleftherios P Diamandis
Journal:  Mol Cancer Res       Date:  2012-09-28       Impact factor: 5.852

7.  MicroRNA-182 drives metastasis of primary sarcomas by targeting multiple genes.

Authors:  Mohit Sachdeva; Jeffrey K Mito; Chang-Lung Lee; Minsi Zhang; Zhizhong Li; Rebecca D Dodd; David Cason; Lixia Luo; Yan Ma; David Van Mater; Rebecca Gladdy; Dina C Lev; Diana M Cardona; David G Kirsch
Journal:  J Clin Invest       Date:  2014-09-02       Impact factor: 14.808

8.  ARNTL2 and SERPINE1: potential biomarkers for tumor aggressiveness in colorectal cancer.

Authors:  Gianluigi Mazzoccoli; Valerio Pazienza; Anna Panza; Maria Rosa Valvano; Giorgia Benegiamo; Manlio Vinciguerra; Angelo Andriulli; Ada Piepoli
Journal:  J Cancer Res Clin Oncol       Date:  2011-12-24       Impact factor: 4.553

9.  Cerebrovascular Remodeling and Neuroinflammation is a Late Effect of Radiation-Induced Brain Injury in Non-Human Primates.

Authors:  Rachel N Andrews; Linda J Metheny-Barlow; Ann M Peiffer; David B Hanbury; Janet A Tooze; J Daniel Bourland; Robert E Hampson; Samuel A Deadwyler; J Mark Cline
Journal:  Radiat Res       Date:  2017-03-06       Impact factor: 2.841

10.  Display of cell surface sites for fibronectin assembly is modulated by cell adherence to (1)F3 and C-terminal modules of fibronectin.

Authors:  Jielin Xu; Eunnyung Bae; Qinghong Zhang; Douglas S Annis; Harold P Erickson; Deane F Mosher
Journal:  PLoS One       Date:  2009-01-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.